CIENCIASMEDICASNEWS: FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement | FDA

lunes, 29 de agosto de 2022

FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement | FDA

FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)